Clinical Insights: Five-year Follow-up of KEYNOTE-189 Trial Outcomes and More

Overview

Journal Transl Lung Cancer Res

Date 2024 Sep 12

PMID 39263022

Authors

Bobby Se

Athar Eysa

Nagla Karim

Affiliations

Soon will be listed here.

References

El Zarif T, Nassar A, Adib E, Fitzgerald B, Huang J, Mouhieddine T . Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. J Clin Oncol. 2023; 41(21):3712-3723. PMC: 10351941. DOI: 10.1200/JCO.22.02459. View

Corrigan K, Rooney M, Kouzy R, Manzar G, Thomas Jr C, Ludmir E . Selection and Prejudice: Addressing Clinical Trial Disparities With a Review of Current Shortcomings and Future Directions. Semin Radiat Oncol. 2023; 33(4):367-373. PMC: 11835201. DOI: 10.1016/j.semradonc.2023.06.002. View

Garassino M, Gadgeel S, Speranza G, Felip E, Esteban E, Domine M . Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol. 2023; 41(11):1992-1998. PMC: 10082311. DOI: 10.1200/JCO.22.01989. View

Lurain K . Treating Cancer in People With HIV. J Clin Oncol. 2023; 41(21):3682-3688. PMC: 10351946. DOI: 10.1200/JCO.23.00737. View

Wu P, Van Scoyk M, McHale S, Chou C, Riddick G, Farouq K . Cooperation between PRMT1 and PRMT6 drives lung cancer health disparities among Black/African American men. iScience. 2024; 27(2):108858. PMC: 10830871. DOI: 10.1016/j.isci.2024.108858. View

Gadgeel S, Rodriguez-Abreu D, Speranza G, Esteban E, Felip E, Domine M . Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2020; 38(14):1505-1517. DOI: 10.1200/JCO.19.03136. View

Ponder R . A Protected Class, An Unprotected Condition, and A Biomarker - A Method/Formula for Increased Diversity in Clinical Trials for the African American Subject with Benign Ethnic Neutropenia (BEN) - CORRIGENDUM. Am J Law Med. 2023; 49(4):525. DOI: 10.1017/amj.2023.24. View

de Castro Jr G, Kudaba I, Wu Y, Lopes G, Kowalski D, Turna H . Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study. J Clin Oncol. 2022; 41(11):1986-1991. PMC: 10082298. DOI: 10.1200/JCO.21.02885. View

Shiraishi Y, Kishimoto J, Sugawara S, Mizutani H, Daga H, Azuma K . Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2023; 10(3):315-324. PMC: 10739077. DOI: 10.1001/jamaoncol.2023.5258. View

10.

Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F . Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 378(22):2078-2092. DOI: 10.1056/NEJMoa1801005. View